WORCESTER, Mass., June 25, 2007 (PRIME NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today at the 67th Scientific Sessions of the American Diabetes Association in Chicago that the Company is preparing to commence a Phase III clinical trial of Generex Oral-lyn(tm), the Company’s proprietary oral insulin spray product. The Company has been establishing regulatory and clinical management teams to execute the trials in the United States and abroad. The clinical trial will be undertaken pursuant to a Phase III protocol approved by Health Canada. The United States Food and Drug Administration’s review period for the protocol recently lapsed without objection.
